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The transient receptor potential channel, TRPM4, and its closest homolog, TRPM5, are
non-selective cation channels that are activated by an increase in intracellular calcium.
They are expressed in many cell types, including neurons and myocytes. Although the
electrophysiological and pharmacological properties of these two channels have been
previously studied, less is known about their regulation, in particular their post-translational
modifications. We, and others, have reported that wild-type (WT) TRPM4 channels
expressed in HEK293 cells, migrated on SDS-PAGE gel as doublets, similar to other
ion channels and membrane proteins. In the present study, we provide evidence that
TRPM4 and TRPM5 are each N-linked glycosylated at a unique residue, Asn992 and Asn932,
respectively. N-linked glycosylated TRPM4 is also found in native cardiac cells. Biochemical
experiments using HEK293 cells over-expressing WT TRPM4/5 or N992Q/N932Q mutants
demonstrated that the abolishment of N-linked glycosylation did not alter the number
of channels at the plasma membrane. In parallel, electrophysiological experiments
demonstrated a decrease in the current density of both mutant channels, as compared to
their respective controls, either due to the Asn to Gln mutations themselves or abolition
of glycosylation. To discriminate between these possibilities, HEK293 cells expressing
TRPM4 WT were treated with tunicamycin, an inhibitor of glycosylation. In contrast
to N-glycosylation signal abolishment by mutagenesis, tunicamycin treatment led to an
increase in the TRPM4-mediated current. Altogether, these results demonstrate that
TRPM4 and TRPM5 are both N-linked glycosylated at a unique site and also suggest that
TRPM4/5 glycosylation seems not to be involved in channel trafficking, but mainly in their
functional regulation.
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INTRODUCTION
TRPM4, and its closest homolog TRPM5, are members of the
transient receptor potential (TRP) ion channel gene family
(Clapham et al., 2005; Ramsey et al., 2006). As with all TRP
channels, they consist of tetramers of alpha subunits and each
monomer contains six transmembrane segments. The selectivity
filter is located in the loop connecting the fifth and sixth trans-
membrane domains. The cytoplasmic N- and C-termini contain a
number of potential protein-protein interaction domains (Nilius
et al., 2005b). TRPM4 and TRPM5 channels are both activated
by an increase in intracellular calcium and are only permeable to
monovalent cations, such as sodium and potassium. In humans,
TRPM4 is expressed in many cell types (Nilius et al., 2004). The
human TRPM4b long splice variant is the only form that has
been shown to mediate ionic current in heterologous expression
systems, whereas the role of the short splice TRPM4a variant
remains unknown (Murakami et al., 2003; Nilius et al., 2004).
In the present study, we investigated the functional splice vari-
ant TRPM4b (subsequently referred to as TRPM4) and its closest
homolog TRPM5.
Thus, far, the roles of TRPM4 have mainly been studied in
immune cells (Launay et al., 2004; Barbet et al., 2008; Shimizu
et al., 2009), pancreatic beta cells (Cheng et al., 2007), arterial
and venous smooth muscle cells (Gonzales et al., 2010; Simard
et al., 2010), skeletal muscle cells (Kruger et al., 2008), adrenal
gland chromaffin cells (Mathar et al., 2010), cardiac cells
(Guinamard et al., 2006a,b; Demion et al., 2007; Guinamard,
2007; Mathar et al., 2013), and neuronal cells (Schattling et al.,
2012; Kim et al., 2013). TRPM5 has been shown to play an
important role in taste sensory cells (Zhang et al., 2007) and
in neurons (Egorov et al., 2002, 2006; Teruyama et al., 2011).
The importance of TRPM4 in disease has been underlined by
the observation that many pathogenic genetic variants have been
found in patients with cardiac conduction disorders (Abriel et al.,
2012), and that TRPM4 knock-out mice develop less neurologi-
cal alterations in a mouse model of multiple sclerosis (Schattling
et al., 2012).
A growing number of studies show that post-translational
modification of TRPM4, such as phosphorylation by PKC (Earley
et al., 2007; Crnich et al., 2010) and SUMOylation, play a role
in regulating their density at the plasma membrane (Kruse et al.,
2009; Liu et al., 2010). In addition, TRPM4 Western blots show
that it migrates in SDS-PAGE gels as two distinct bands, suggest-
ing that it may be glycosylated (Amarouch et al., 2013; Woo et al.,
2013b). Thus, far, the molecular determinants and the function
of this glycosylation are only partially understood.
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In this work, we usedHEK293 cells transiently transfected with
either TRPM4 or TRPM5 to investigate whether these channel
proteins are glycosylated, and to determine the functional conse-
quences of this post-translational modification. Biochemical and
pharmacological experiments using mutant forms of TRPM4/5
channels revealed a unique N-glycosylation site close to the
selectivity filter. Cell surface biotinylation experiments and patch-
clamp recording in whole cell configuration suggest that TRPM4
and TRPM5 glycosylation plays a role in their function as channel
proteins rather than for their expression at the plasmamembrane.
The results of the present study confirm and expand previous
results, but at the same time highlight several differences to a
recent study by Woo et al. (2013a).
EXPERIMENTAL PROCEDURES
PLASMIDS
Two plasmids, human HA-TRPM4 WT (GenBank AF497623;
Uniprot Q8TD43-1) and TRPM5 WT (GenBank NM_014555.3;
Uniprot Q9NZQ8-1), were received from Dr. Bouvagnet
(University of Lyon, France) and from Dr. Vennekens (University
of Leuven, Belgium), respectively. The constructs were mutage-
nized using Quickchange II XL (Agilent, Santa Clara, California,
USA), according to the manufacturer’s protocol. The primer
sequences (5′ to 3′) used for mutagenesis were as follows:
S TRPM4 a2974c_c2976g TCATGGAGCACAGCCAGTGCTCGT
CGGAGCC, AS TRPM4 a2974c_c2976g GGCTCCGACGAGCAC
TGGCTGTGCTCCATGA, S TRPM5 a2794c_c2796g ATGA
AGCCCGTGTGCAGTGCTCCACCCACCC, AS TRPM5 a2794c_
c2796g GGGTGGGTGGAGCACTGCACACGGGCTTCAT.
TRANSFECTIONS
For biochemical experiments, HEK293 cells were individually
transiently transfected with the following plasmids: 240 ng of HA-
TRPM4 WT or HA-TRPM4 N992Q, 2μg of either TRPM5 WT
or TRPM5 N932Q in a P100 dish (BD Falcon, Durham, North
Carolina, USA), mixed with 30μl of JetPEI (Polyplus transfec-
tion, Illkirch, France) and 250μl of 150mM NaCl. The cells were
incubated for 48 h at 37◦C with 5% CO2. For electrophysio-
logical studies, T25 cm2 flasks of HEK293 cells were transiently
co-transfected using X-tremeGENE 9 DNA transfection mix
reagent (Roche Diagnostics, IN, USA) with 0.3μg of WT, mutant
TRPM4, or TRPM5 channels. These transfections included 0.2μg
of cDNA encoding CD8 antigen as a reporter gene. Anti-CD8
beads(Dynal, Oslo, Norway) were used to identify transfected
cells,and only CD8-displaying cells were analyzed.Cells were used
48 h after transfection.
CELL SURFACE BIOTINYLATION ASSAYS
Following 48 h of incubation, transiently transfected HEK293
cells previously washed twice with cold 1x PBS were treated with
0.5mg/ml EZ-link™ Sulfo-NHS-SS-Biotin (Thermo Scientific,
Rockford, Illinois, USA) in cold 1X PBS for 15min at 4◦C.
Subsequently, the cells were washed twice with 200mMGlycine in
cold 1X PBS and twice with cold 1X PBS to inactivate and remove
the excess biotin, respectively. The cells were then lysed with
1X lysis buffer [50mM HEPES pH 7.4; 150mM NaCl; 1.5mM
MgCl2; 1mM EGTA pH 8; 10% Glycerol; 1% Triton X-100;
1X Complete Protease Inhibitor Cocktail (Roche, Mannheim,
Germany)] for 1 h at 4◦C. Cell lysates were centrifuged at 16,000 g,
4◦C for 15min. Two milligrams of the supernatant were incu-
bated with 50μl Streptavidin Sepharose High Performance beads
(GE Healthcare, Uppsala, Sweden) for 2 h at 4◦C, and the remain-
ing supernatant was kept as the input. The beads were subse-
quently washed five times with 1X lysis buffer before elution
with 50μl of 2X NuPAGE sample buffer (Invitrogen, Carlsbad,
California, USA) plus 100mM DTT at 37◦C for 30min. These
biotinylated fractions were analyzed as TRPM4 expressed at the
cell surface. The input fractions, analyzed as total expression of
TRPM4, were resuspended with 4X NuPAGE Sample Buffer plus
100mM DTT, yielding a concentration of 1mg/ml, and then
incubated at 37◦C for 30min.
DEGLYCOSYLATION ASSAYS
Deglycosylation with PNGase F and Endo H. HEK293 cells
or homogenized human atrial samples were lysed with 1X
lysis buffer [50mM HEPES pH 7.4; 150mM NaCl; 1.5mM
MgCl2; 1mM EGTA pH 8.0; 10% Glycerol; 1% Triton X-100;
1X Complete Protease Inhibitor Cocktail (Roche, Mannheim,
Germany)] for 1 h at 4◦C. The lysates were then centrifuged at
16,000 g, 4◦C for 15min. Forty micrograms of these lysates were
denatured for 30min at 37◦C in the presence of 1X Glycoprotein
denaturing buffer and bidistilled H2O in a total volume of 21μl.
Following this incubation, glycosylation mix was added [PNGase
F mix: 1X G7 buffer, 1X NP40 and 1500 units PNGase F; Endo H
mix: 1X G5 buffer and 3000 units Endo H (New England Biolabs,
Ipswich, MA, USA)] to the denatured samples and incubated for
1 h at 37◦C. To stop the reaction, 10μl of 4X NuPAGE sample
buffer (Invitrogen, Carlsbad, California, USA) plus 100mMDTT
were added to the deglycosylated samples. For deglycosylation
on biotinylated samples, denaturation was performed after the
2 h incubation of whole cell lysates with streptavidin beads. After
aspirating the lysate, 35μl of bidistillated H2O and 5μl of 10X
Glycoprotein denaturing buffer were added prior to denaturation
at 37◦C for 30min. Following this incubation, the glycosylation
mix (PNGase F mix: 6μl 10X G7 buffer, 6μl 10X NP40 and 2000
units PNGase F or Endo H mix: 6μl 10X G5 buffer and 4000
units Endo H) was added to the denatured samples and incubated
for 1 h at 37◦C. The samples were subsequently washed five times
with the same lysis buffer (800 g, 4◦C, 2min) before elution with
50μl of 2X NuPAGE sample buffer plus 100mM DTT at 37◦C
for 30min. Human tissue acquisition was performed in accor-
dance with the Institutional Review Board and individual patient
consent was obtained.
WESTERN BLOT
Protein samples were analyzed on 9% polyacrylamide gels,
transferred with the TurboBlot dry blot system (Biorad,
Hercules, CA, USA) and detected with anti-TRPM4 (gen-
erated by Pineda, Berlin, Germany), anti-TRPM5 ab154788
(Abcam, Cambridge, UK), anti-Na+/K+ ATPase α1 ab7671
(Abcam, Cambridge, UK) and anti α-actin A2066 (Sigma, St.
Louis, Missouri, USA) antibodies using SNAP i.d. (Millipore,
Billerica, MA, USA). The anti-TRPM4 antibody was generated by
Pineda (Berlin, Germany) using the following peptide sequence:
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NH2-CRDKRESDSERLKRTSQKV-CONH2. A fraction of the
antisera, which was subsequently used in this study, was then
affinity purified.
CELLULAR ELECTROPHYSIOLOGY
Whole-cell currents were measured at room temperature
(22–23◦C) using a VE-2 (Alembic Instruments) amplifier.
Pipette solution contained (in mM): 100 CsAspartate, 20 CsCl,
4 Na2ATP, 1MgCl2, and 10 HEPES. The pH was adjusted to
7.2 with CsOH, and the Ca2+ free concentration ranged to
100μM calculated by WEBMAXCLITE program (http://www.
stanford.edu/∼cpatton/downloads.htm). Bath solutions con-
tained (in mM): 156NaCl, 1.5 CaCl2, 1MgCl2, 6 CsCl 10
D-glucose, and 10 HEPES. The pH was adjusted to 7.4 with
NaOH. Data were analyzed using pClampsoftware, version 10.2
(Axon Instruments, Union City, California, USA).
DRUGS
Tunicamycin was purchased from Sigma-Aldrich (Sigma-Aldrich,
Dorset, United Kingdom) and was dissolved in DMSO. DMSO
did not exceed 0.1% in the final solution.
STATISTICAL ANALYSIS
Data are presented as mean ± s.e.m. Unpaired, two-tailed
Student’s t-test was used to compare the means; p < 0.05 was
considered significant.
RESULTS
TRPM4 CHANNEL IS N-LINKED GLYCOSYLATED AT Asn992
As membrane proteins are often glycosylated and TRPM4 was
migrating as a distinct doublet on SDS-PAGE gels, TRPM4
was then searched for the presence of an N-glycosylation
consensus sequence Asn-Xaa-Ser/Thr (Xaa being any amino
acid except Pro and Asp), using the publicly available pro-
gramme NetNGlyc 1.0 Server (http://www.cbs.dtu.dk/services/
NetNGlyc). A putative N-glycosylation motif, Asn-Cys-Ser at
residue Asn992 (Figure 1A), located after the selectivity filter
(981-EDMDVA-986) between segment 5 and 6 (Figure 1B), was
detected. This consensus sequence is conserved in humans, mice,
and rats (Figure 1A), while among other TRPM channels, only
TRPM5 displays a similar signal at residue Asn932 (Figures 1A,B).
To test the hypothesis that Asn992 is the TRPM4 glycosylation site,
Asn was mutated into Gln (N992Q) to enable the investigation
of the cell biology and functional roles of TRPM4 glycosylation.
As illustrated in Figure 2, WT TRPM4 runs as a distinct doublet
(Figure 2A) in Western blot experiments. The N992Q mutation
resulted in a single band running faster than the lower band
of the WT protein (compare lanes 3 and 5 in Figure 2A). This
band was unaffected by treatment with Peptide-N-glycosidase F
(PNGase F), which trims all N-linked glycosylation modifica-
tions (Figure 2A lane 6). Thus, this band was subsequently named
unglycosylable TRPM4. Upon treatment with PNGase F, the two
bands seen in the WT were also shifted into a single band run-
ning at the same height as the unglycosylable band (compare
lanes 4 and 5 in Figure 2A). This observation led us to conclude
that the upper and lower bands are fully- and core glycosylated
TRPM4 fractions, respectively, and that Asn992 is the unique
glycosylation site of TRPM4. The lanes where lysates of non-
transfected HEK293 cells were loaded (empty in Figure 2A) show
similar findings as theWT, albeit with much fainter signals. These
bands are most likely endogenous TRPM4 expressed in HEK293
cells, as previously reported by our group (Amarouch et al., 2013).
To further confirm that glycosylated TRPM4 exists in vivo, total
protein from a piece of human cardiac atria was isolated and
treated with PNGase F. As demonstrated in Figure 2B, endoge-
nous cardiac TRPM4 ran as a distinct doublet (lane 1), which
shifted into a single band (lane 2) running slightly lower than the
core glycosylated band when treated with PNGase F. This result
demonstrated that fully- and core glycosylated forms of TRPM4
are endogenously expressed in cardiac cells.
GLYCOSYLATION IS NOT ESSENTIAL FOR THE EXPRESSION OF TRPM4
AT THE CELL SURFACE
To determine whether glycosylation is essential for TRPM4 trans-
port and expression at the cell surface, cell surface biotinylation
assays were performed. As shown in Figure 2C (lanes 3 and 6),
TRPM4 N992Q mutant was well expressed both in the whole
cell lysate and at the cell surface, despite being unglycosylated
(Figure 2C). This experiment suggests that glycosylation is not
essential for expression of TRPM4 at the cell surface.
TRPM4 N-GLYCOSYLATION TYPES ARE DIFFERENT IN THE
INTRACELLULAR FRACTION AND AT THE CELL SURFACE
In order to obtain more information about the N-glycosylation
identity of TRPM4, TRPM4 was treated with endoglycosi-
dase H (Endo H) in addition to PNGase F. While PNGase
F trims all N-linked glycosylation (high mannose, hybrid
and complex oligosaccharides) from the innermost GlcNAc
(N-Acetylglucosamine) that is linked to an Asn residue, Endo H
only trims high mannose and certain hybrid oligosaccharides, but
not complex oligosaccharides (Maley et al., 1989). As illustrated
in Figure 2D, PNGase F completely trims TRPM4 in total and
biotinylated fractions (Figure 2D lanes 4 and 8). However, Endo
H only trims a part of glycosylated TRPM4 in the input frac-
tion (Figure 2D lane 3), and none in the biotinylated fraction
(Figure 2D lane 7). This observation suggests that TRPM4 has
a significant amount of complex oligosaccharides and a minor
amount of high mannose and/or hybrid oligosaccharides in the
total fraction where TRPM4 is mostly intracellular, while only
complex oligosaccharides exist at the cell surface.
THE N992Q MUTANT DECREASES TRPM4 CURRENT DENSITY
Amarouch et al. (2013) used the patch clamp technique in whole-
cell configuration with HEK293 cells, to demonstrate that the
TRPM4-mediated current recorded over time shows two distinct
phases (Figure 3A). A transient phase appears quickly after the
rupture of the membrane patch, and then a plateau phase appears
1–3min later (Figure 3A). To investigate the consequences of the
N992Q mutation on TRPM4 function, the transient and plateau
current density were recorded at +100mV and −100mV using
a ramp protocol (Figure 3B). The quantification of both groups
(WT and N992Q) showed a statistically significant decrease in
current density of both the transient and plateau phases (WT
vs. N992Q transient: 161 ± 38 pA/pF n = 8 vs. 27 ± 7 pA/pF
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FIGURE 1 | N-glycosylation site of TRPM4 and TRPM5. (A) A bioinformatic
search reveals a putative site for N-linked glycosylation in TRPM4 that is
conserved in different organisms and the closely related TRPM5.
(B) Illustration showing the location of N-linked glycosylation site in the
pore-forming region between transmembrane segments 5 and 6 of TRPM4
and TRPM5.
n = 6; plateau: 604 ± 53 pA/pF n = 8 vs. 327 ± 62 pA/pF n = 6)
(Figures 3B,C). In addition, the deactivation kinetics of TRPM4
at the end of the step at +100mV and −100mV were faster
with the N992Q mutant compared to WT (Figure 3B). Due to
the extremely fast deactivation at −100mV, this parameter was
only quantified at +100mV (WT 3749 ± 471 pA/s n = 9 vs.
N992Q−90± 139 pA/s n = 8, p < 0.05). In parallel, the current-
voltage (I-V) relationship, performed during the plateau phase,
did not reveal any drastic alterations in the voltage-dependence
of the mutant channel (Figure 3D).
TRPM5 CHANNEL IS N-LINKED GLYCOSYLATED AT Asn932
Similar experiments were performed with TRPM5, since it is
the closest relative of TRPM4 in the TRPM channel family and
it has a similar N-glycosylation signal, Asn-Cys-Ser, at residue
Asn932 (Figure 1A). To test the hypothesis that Asn932 is where
the glycoside residues link to TRPM5, Asn was mutated into
Gln (N932Q). Using the same SDS-PAGE running conditions as
for TRPM4, a lower band and a smeary upper band, presum-
ably the core- and fully glycosylated bands, respectively, were
observed with WT TRPM5 (Figure 4A lane 3). At the same time,
the TRPM5 N932Q mutant appeared as a single band running
faster than the lower band of the WT (Figure 4A lane 5), and this
was concluded to be the unglycosylable band. When treated with
PNGase F, the WT bands shifted into a single band (Figure 4A
lane 4) running at the same height as the mutant band. This
result confirms that Asn932 is the unique N-glycosylation site of
TRPM5, and that the upper and lower bands are the fully- and
core glycosylated bands of TRPM5, respectively.
GLYCOSYLATION IS NOT ESSENTIAL FOR THE EXPRESSION OF TRPM5
AT THE PLASMAMEMBRANE
After concluding that glycosylation of TRPM4 is not essential
for its expression at the cell surface, tests were performed to
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FIGURE 2 | Deglycosylation and cell surface biotinylation of TRPM4.
(A) Treatment with Peptide N-glycosidase F (PNGase F) demonstrates
that the unglycosylated WT TRPM4 has a similar molecular weight to the
TRPM4 N992Q mutant in HEK293 cells transiently transfected with WT
or N992Q mutant. (B) Treatment of TRPM4 isolated from human cardiac
atria with PNGase F shows that glycosylation is also found on TRPM4
from native tissues. Lane 4 is a lower exposure image of lane 3. All
samples were run and blotted on the same membrane with
rearrangement intended for clarity purposes. (C) Cell surface biotinylation
of HEK293 cells transiently transfected with WT or TRPM4 N992Q
mutant constructs shows expression of both WT and mutant at the total
level and at the cell surface. (D) Treatment with Endo H only removes
some of the glycosylation in the input fraction, but not in the biotinylated
fraction.
determine if this was also the case for TRPM5. Despite being
unglycosylated, the TRPM5 N932Q mutant was well expressed
and could be found in both the total fraction as well as the cell
surface (Figure 4B lanes 3 and 6). This suggests that glycosylation
is not essential for TRPM5 expression at the cell surface. The
faint upper band observed in lanes 4 and 6 of Figure 4B
may represent endogenous TRPM5 expressed in HEK293
cells.
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FIGURE 3 | Whole cell patch clamp recording of WT and TRPM4
N992Q mutant transiently transfected in HEK293 cells. (A) Current
density of TRPM4 over time shows a brief transient and a long
persistent plateau phase. (B) Individual currents recorded using a ramp
protocol depicted in the inset. (C) Quantification at +100mV of WT
and TRPM4 N992Q mutant current densities during the transient (left
panel) and plateau (right panel) phases in dot plot graph shows a
significant decrease in current densities in both phases compared to
TRPM4 WT. (D) Current vs. voltage relationship shows a decreased
current in TRPM4 N992Q mutant without major alterations of the
voltage-dependence. Statistical test using two-tailed Student T -test
∗P < 0.05, ∗∗P < 0.01.
TRPM5 N-GLYCOSYLATION TYPES ARE SIMILAR IN THE
INTRACELLULAR FRACTION AND AT THE CELL SURFACE
To learn more about the glycosylation identity of TRPM5,
TRPM5 was treated with Endo H in addition to PNGase F, as was
done for TRPM4. While PNGase F completely trimmed TRPM5
(Figure 4C lanes 4 and 8), Endo H only trimmed a small fraction
of TRPM5 (Figure 4C lanes 3 and 7). Since no differences in the
patterns between total and biotinylated fractions were observed,
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FIGURE 4 | Deglycosylation and biotinylation of TRPM5. (A)
Treatment with PNGase F demonstrates that unglycosylated WT TRPM5
has a similar molecular weight to the TRPM5 N932Q mutant. (B) Cell
surface biotinylation of HEK293 cells transiently transfected with WT or
TRPM5 N932Q mutant constructs shows expression of both WT and
mutant at the total level and at the cell surface. (C) Treatment with
Endo H removes some of the glycosylation in both input and
biotinylated fractions.
TRPM5 was concluded to have a majority of complex oligosac-
charides with some minor amounts of high mannose and hybrid
oligosaccharides in both fractions.
TRPM5 CURRENT DENSITY IS DECREASED WITH THE N932Q MUTANT
Functional experiments using the similar patch clamp tech-
nique as was done for TRPM4 were performed. In the case of
TRPM5, only one phase was observed after rupture of the mem-
brane patch. The recordings revealed a statistically significant
decrease in the current density at+100mV for theN932Qmutant
compared to WT (WT vs. N932Q: 848 ± 55 pA/pF n = 5 vs.
136 ± 26 pA/pF n = 5) (Figures 5A,B). No major alterations in
the biophysical properties were observed (Figure 5B).
TUNICAMYCIN TREATMENT INCREASES TRPM4 CURRENT DENSITY
Since the TRPM4 N992Q mutation reduced its current without
any striking biophysical alterations, it remained to be determined
whether the effect was primarily dependent on the Asn to Gln
mutation itself or on the consequence of the mutation, i.e.,
the lack of TRPM4 glycosylation. Thus, HEK293 cells tran-
siently expressing either WT TRPM4 or N992Q mutant were
treated with tunicamycin, an inhibitor of N-linked glycan syn-
thesis. Tunicamycin treatment at 10μg/ml for 19 h decreased
the upper band by approximately 60%, as shown in Figure 6A.
Somewhat unexpectedly, this treatment led to a statistically sig-
nificant increase in both the transient and plateau current densi-
ties of TRPM4 WT (normalized untreated vs. treated transient;
100 ± 27% n = 5 vs. 494 ± 129% n = 5 and plateau; 100 ±
6% n = 5 vs. 202 ± 29% n = 5) (Figure 6B) without modify-
ing the I-V relationship (Figure 6C) or the deactivation kinetics
at +100mV (WT DMSO 4855 ± 379 pA/s n = 5 vs. WT tuni-
camycin 5265 ± 572 pA/s n = 5, p > 0.05). Importantly, the
same treatment on HEK293 cells expressing TRPM4 N992Q
neither altered the current density recorded during both phases
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FIGURE 5 | Whole cell patch clamp recording of WT and TRPM5 N932Q
mutant transiently transfected in HEK293 cells. (A) Individual currents
recorded using a ramp protocol depicted in the inset. (B) Current vs. voltage
relationship shows a decreased current in TRPM5 N932Q mutant without
major alterations of the biophysical properties. Statistical test using two-tailed
Student T -test ∗P < 0.05, ∗∗P < 0.01.
(untreated vs. treated transient; 100 ± 26% n = 5 vs. 102 ± 40%
n = 6 and plateau; 100± 31% n = 5 vs. 92± 18% n = 6) nor the
I-V relationship (Figures 6B,C). This suggests that the observed
current density increase with TRPM4 WT under tunicamycin
treatment is dependent on glycosylation of Asn992 (Figures 6A,B)
and indicates that the N992Q-mediated current decrease depends
on the mutation itself.
DISCUSSION
The main finding of this study is that in heterologous expres-
sion systems TRPM4 and TRPM5 are N-linked glycosylated,
while TRPM4 was also found to be glycosylated in cardiac tis-
sues. Furthermore, it was observed that this N-glycosylation
occurs (1) via a unique site located in the pore-forming
region, (2) may not play a significant role in trafficking to
the plasma membrane, (3) can be of different types, and
(4) is involved in modulating the current density at the cell
surface.
GLYCOSYLATION OF TRPM4/5 CHANNELS
The pore region of the TRP channel, known to harbor the
selectivity filter, may appear to be an unusual site for glycosy-
lation. Several recent reports, however, have shown that TRPV1
and TRPV4 also have a unique N-glycosylation site in the same
domain (Xu et al., 2006; Veldhuis et al., 2012). Furthermore, as
cited by Cohen (2006), TRPV2 and TRPV3 are predicted to have
N-glycosylation sites in the same region. Very recently, Woo et al.
(2013a) investigated the site and the role of N-linked glycosyla-
tion of the mouse TRPM4. They showed biochemical evidence
for TRPM4 glycosylation in native rat tissues, suggesting that
this post-translational modification likely plays an important role
in vivo. In the present work, we obtained evidence that fully-
and core glycosylated forms of TRPM4 are expressed in human
cardiac atrial tissue.
FORWARD TRAFFICKING AND GLYCOSYLATION
N-linked protein glycosylation has been shown to be crucial for
the trafficking of several ion channels toward the plasma mem-
brane, i.e., Kv11.1 (hERG channel) (Petrecca et al., 1999) and
Shaker channels (Khanna et al., 2001). In contrast, despite not
having glycosylation, mutant TRPM4/5 and WT TRPM4/5 from
tunicamycin-treated cells were well expressed at the plasmamem-
brane, suggesting that N-glycosylation may not play an essential
role in the forward trafficking.Woo and co-workers recently came
to a similar conclusion (Woo et al., 2013a). Others have also
reported that glycosylation is not essential for the forward traf-
ficking of membrane proteins, such as TRPV5 (Leunissen et al.,
2013), organic solute transporter alpha (Soroka et al., 2008) and
proline-rich membrane anchor (Chan et al., 2012). In addition
to the regulation of forward trafficking, N-glycosylation most
likely has other important cellular functions, such as cell adhe-
sion, self/non-self-recognition, receptor activation and endocyto-
sis (Ohtsubo and Marth, 2006).
COMPLEX OLIGOSACCHARIDES AND THEIR ROLE IN TRPM4/5
REGULATION
As shown in Figure 2C, we observed that TRPM4 can have
different types of N-glycosylation in the intracellular fraction
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FIGURE 6 | Effect of tunicamycin treatment on WT and TRPM4 N992Q
mutants. (A) Cell surface biotinylation of HEK293 cells transiently
transfected with WT or TRPM4 N992Q mutant constructs and pretreated
with tunicamycin (10μg/ml; 19 h) demonstrates a reduction of the
glycosylated bands of TRPM4 following the treatment. Western blots shown
in upper panels with quantification in lower panels (treated 38 ± 13% vs.
untreated 100 ± 00% n = 4 in the input fraction; treated 38 ± 11% vs.
untreated 100 ± 00% n = 3 in the biotinylated fraction; p < 0.05) (B)
Quantification in dot plot graph of WT and N992Q mutant current densities
at +100mV shows a significant increase in the transient and plateau current
densities after tunicamycin treatment (10μg/ml; 19 h) only with the WT
(transient: untreated 123 ± 37 pA/pF n = 5 vs. treated 610 ± 178 pA/pF
n = 5; p < 0.05; plateau: untreated 657 ± 41 pA/pF n = 5 vs. treated 1327 ±
210 pA/pF n = 5; p < 0.05), but not with the N992Q mutant (transient:
untreated 23 ± 6 pA/pF n = 5 vs. treated 23 ± 10 pA/pF n = 6; plateau:
untreated 426 ± 147 pA/pF n = 5 vs. treated 391 ± 83 pA/pF n = 6).
Untreated: vehicle (DMSO). (C) Current vs. voltage relationship shows an
increase of current in TRPM4 WT condition after tunicamycin treatment,
without major alterations in voltage dependence. Statistical test using
two-tailed Student T -test ∗P < 0.05, ∗∗P < 0.01.
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(with a significant amount of complex oligosaccharides and a
minor amount of high mannose and/or hybrid oligosaccharides),
and at the cell surface (exclusively with complex oligosaccha-
rides). Woo et al. (2013a) also showed analogous results for the
total protein fraction, although they only mentioned the presence
of high mannose in TRPM4. The significant amount of com-
plex oligosaccharides found in the total fraction (intracellular),
which are a mix of cytoplasm, endoplasmic reticulum (ER), Golgi
apparatus, plasma membrane might come from the bulk TRPM4
Golgi and/or downstream compartments where TRPM4 is mostly
glycosylated with complex oligosaccharides. Nonetheless, we can-
not rule out the possibility that ER membranes were not effi-
ciently disrupted to release ER-bound TRPM4 which is most
likely glycosylated with high mannose and/or oligosaccharides.
Such a difference of glycosylation types in the two fractions was,
however, not observed with TRPM5, despite the fact that the site
of glycosylation is found in a homologous domain. It is also inter-
esting to note that most membrane proteins are glycosylated with
complex oligosaccharides, but not with high mannose and/or
hybrid oligosaccharides at the cell surface. However, we observed
that TRPM5 is glycosylated with a significant amount of com-
plex oligosaccharides and a minor amount of high mannose and
hybrid oligosaccharides both intracellularly and at the cell sur-
face. Others groups (Tulsiani et al., 1992; Kuo et al., 1996; Meschi
et al., 2005), however, have found high mannose and/or hybrid
oligosaccharides on plasma membrane-bound proteins. Taking
these observations into account, it is possible to find TRPM5 gly-
cosylated with high mannose and/or hybrid oligosaccharides at
the cell surface.
UNGLYCOSYLABLE TRPM4/5 MUTANTS
In the present study, the consequences of the Asn to Gln muta-
tions on the function of the TRPM4/5 channels were further
investigated. The unglycosylable TRPM4/5 mutants displayed
strikingly decreased current amplitudes compared to their respec-
tive controls, despite the fact that their total protein expression
at the cell surface was not altered. This finding suggests that
N-glycosylation of TRPM4/5 has a stronger impact on the chan-
nel’s function than on its expression at the plasma membrane.
Nevertheless, the observed discrepancy between the biochemistry
and functional findings is puzzling. It may be that the decreased
TRPM4/5 current densities are caused by the mutation itself,
rather than by the fact that the channels are not glycosylated.
Woo et al. (2013a) showed that the single channel conductance
of the mouse TRPM4 channel, which harbors the homologous
Asn to Gln mutation, was not altered. It may be, however, that the
observed whole-cell current reduction could be due to alterations
of open probability that were not measured by the authors.
TUNICAMYCIN TREATMENT OF WT AND UNGLYCOSYLABLE TRPM4
Since the N-glycoslyation signal (Asn992) of TRPM4 is close to its
selectivity filter, the observed current decrease with the N992Q
mutant could be due to either an alteration of TRPM4 gating
mediated directly by the mutation itself or as a consequence
of absence of glycosylation. To discriminate between these two
possibilities, TRPM4 currents were recorded after treating the
cells with the glycosylation inhibitor, tunicamycin, in order to
determine whether the reduction of the TRPM4 N992Q current
amplitude was mainly a consequence of the lack of glycosylation.
Somewhat unexpectedly, following this treatment both plateau
and transient TRPM4-mediated current densities were greater,
without any evidence of an increase in the number of channels
expressed at the plasma membrane. Importantly, tunicamycin
had no effect on the unglycosylable TRPM4 N992Q mutant.
This finding suggests (1) that the tunicamycin-mediated current
increase was due to the deglycosylation of the channel rather
than the altered glycosylation of other proteins, and (2) that the
N992Q-induced reduction of current was caused by the mutation
itself rather than its effect on glycosylation. As a consequence,
these results indicate that the N992Q mutant is not the most
suitable model for the investigation of the functional roles of
TRPM4 glycosylation. Analogous to the aforementioned reduc-
tion in the current of the unglycosylable mutants, the intensity of
the total TRPM4 protein signal at the cell surface (both fully- and
core glycosylated TRPM4) was not increased after tunicamycin
treatment, while the current density was augmented. These dis-
crepant observations may be due to limitations of the technique.
As observed in Figure 6A, when compared to the untreated con-
dition, the tunicamycin treatment decreased the fully glycosylated
band of TRPM4 WT and increased the intensity of the core
N-glycosylated band. A similar observation was also made by
Leunissen et al. (2013) after Endo F treatment of WT TRPV5.
It is possible that under these conditions the quantification of
the TRPM4 signal is biased because the affinity of the antibody
may vary depending on the N-glycosylation pattern, as has been
previously suggested (Reynard et al., 2004). Another explana-
tion of this discrepancy could be that the TRPM4 single channel
properties are altered after tunicamycin treatment.
CONCLUSIONS
Altogether, the results presented in this study demonstrate
that N-linked glycosylation at a unique site on both TRPM4
and TRPM5 is involved in the regulation of channel activity.
Additionally, these results also suggest that the region surround-
ing the selectivity filter (Nilius et al., 2005a) is involved in the
channel’s function. Further experiments are needed to better
understand the role of this unique glycosylation site in modu-
lating the biophysical properties of both TRPM4 and TRPM5
channels. In summary, we have mapped the N-glycosylation site
of TRPM4/5 and have identified the types of N-glycosylation
displayed by both channels. More importantly, we were able to
demonstrate that glycosylation impacts channel function but not
its surface expression.
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